ライフサイエンスコーパス: nucleoside

1 85% yields, respectively, from the starting nucleoside.

2 robust and scalable approach to this complex nucleoside.

3 osine (dG), the most readily oxidized native nucleoside.

4 pathways such as glycogen, ketone bodies and nucleosides.

5 of cellular RNA with noncanonical pyrimidine nucleosides.

6 py number when supplemented with both purine nucleosides.

7 spirocyclobutanone scaffold for carbocyclic nucleosides.

8 idases that hydrolyse these metabolites into nucleosides.

9 er phosphate groups from tri- to diphosphate nucleosides.

10 We report here the first synthesis of the nucleoside 2-thioorotidine and our observations on its u

11 The HA nucleoside 3, when immobilized in the G-quartet gel, act

12 Nucleoside 5'-triphosphate (dNTP) analogues in which the

13 ved ability to synthesize complex RNAs using nucleoside 5'-triphosphate (NTP) substrates.

14 In vitro, 2'-F-nucleoside 5'-triphosphates were neither inhibitors nor

15 plication errors because of oxidized guanine nucleosides (8-OHdGTPs).

16 tivate NSH2 in vivo, fully preventing purine nucleoside accumulation in nsh1 background.

17 netic marks, and a structurally unidentified nucleoside adduct.

18 spectrometry methodology, we identified DNA nucleoside adducts in gravid females of the Baltic amphi

19 Twenty-three putative nucleoside adducts were detected in the females and thei

20 ponents from other metabolite classes (e.g., nucleosides, alcohols, purine and pyrimidine derivatives

21 with 2'-azidocytidine (2'-AzCyd), a modified nucleoside amenable to bioorthogonal labeling with SPAAC

22 m highly selective assembly of moieties from nucleoside, amino acid, neurotransmitter, and lipid meta

23 leukemia (AML) patients and treated with the nucleoside analog DAC induced genome-wide acetylation ch

24 harmacological intervention of adenosine and nucleoside analog drug transport by hENT1.

25 Resistance to nucleoside analog gemcitabine frequently used in first-l

26 epleting Mdm4 sensitized p53-/- cells to the nucleoside analog gemcitabine, raising the future perspe

27 Monotherapy with interferon or nucleoside analog is generally not recommended during th

28 In this method, a short pulse of nucleoside analog labels replicative regions in the cell

29 milar potency as the clinically administered nucleoside analog reverse transcriptase inhibitor azidot

30 We here show that the nucleoside analog Sangivamycin and its closely-related c

31 Importantly, remdesivir, a broad-spectrum nucleoside analog that is effective against other group

32 Gemcitabine (GMT) is a nucleoside analog used in the treatment of a variety of

33 placement reaction provides a functionalized nucleoside analog.

34 entified by the presence of the incorporated nucleoside analog.

35 kasugamycin, an aminoglycoside; CGS 15943, a nucleoside analog; and Ro 90-7501, a bibenzimidazole.

36 Chain-terminating nucleoside analogs (CTNAs), which cannot be extended by

37 The nucleoside analogs (DAC, 5AC and zebularine) were the mo

38 Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorpor

39 we investigated the relative potency of the nucleoside analogs and non-nucleoside analogs DHAs on DN

40 We also consider existing nucleoside analogs and novel genomic techniques as poten

41 Nucleoside analogs are commonly used in the treatment of

42 While nucleoside analogs are used to relieve symptoms of infec

43 These nucleoside analogs bearing an iodide functional group ha

44 ge, this is the first report to identify the nucleoside analogs DHAs as activators of SIRT6.

45 ve potency of the nucleoside analogs and non-nucleoside analogs DHAs on DNA methylation reversal usin

46 e a rationale against the combination of the nucleoside analogs DHAs with SIRT6 inhibitors or chemoth

47 e present a process for rapidly constructing nucleoside analogs from simple achiral materials.

48 y a common mechanism, such that incorporated nucleoside analogs terminate chain elongation if the res

49 eobases, ranging from 5- to 12-membered ring nucleoside analogs, are generated in excellent yield (up

50 and L21 results in aberrant incorporation of nucleoside analogs, conferring a low fidelity phenotype

51 ighlighted in multigram syntheses of d- or l-nucleoside analogs, locked nucleic acids, iminonucleosid

52 a major target for antiviral drugs including nucleoside analogs, such as the prodrugs mericitabine an

53 rstand the efficiency of inhibition for five nucleoside analogs.

54 iminonucleosides, and C2'- and C4'-modified nucleoside analogs.

55 tide-mediated excision compared with similar nucleoside analogs.

56 s are involved in the cellular uptake of the nucleoside analogue DNA damage mediator 6-thio-2'-deoxyg

57 eling and suggest that EdU is the preferable nucleoside analogue for short pulse-labeling experiments

58 The difference by concomitant nucleoside analogue is unexplained.

59 tivirally active form, the triphosphorylated nucleoside analogue metabolites.

60 Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on p

61 Nucleoside analogue reverse transcriptase (RT) inhibitor

62 erent biodegradable masking units and d4T as nucleoside analogue that enable the delivery of d4TTP wi

63 ar kinases to yield ultimately the bioactive nucleoside analogue triphosphates (NTP).

64 taxel (microtubule stabilizer), gemcitabine (nucleoside analogue) and GDC-0980 (PI3K/mTOR inhibitor).

65 rthermore, SAMHD1 sensitises cancer cells to nucleoside-analogue anti-cancer therapies and is linked

66 ir-boosted lopinavir in combination with two nucleoside analogues (standard of care) for 6 months or

67 onversion from the host, constituting purine nucleoside analogues a potential source of antitrypanoso

68 ation of an undescribed class of carbocyclic nucleoside analogues and provided a proof of concept for

69 Nucleoside analogues are a valuable experimental tool.

70 ts an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the tre

71 onvert some modestly active or even inactive nucleoside analogues into powerful biologically active m

72 The metabolic conversion of nucleoside analogues into their triphosphates often proc

73 The antiviral efficacy of many nucleoside analogues is strongly dependent on their intr

74 structural elements from known trypanocidal nucleoside analogues to develop a series of 3'-deoxy-7-d

75 Some of the most common nucleoside analogues used for pulse-labeling of DNA in c

76 olism, and are important for the delivery of nucleoside analogues used in anticancer drug therapy.

77 rize the biochemical properties of different nucleoside analogues with a given kinase, ultimately lea

78 One class of antiviral compounds, nucleoside analogues, mimics naturally occurring nucleos

79 horylase (Rhodospirillum rubrum) or separate nucleoside and kinase (Escherichia coli) followed by an

80 eived interferon therapy or treatment with a nucleoside and nucleotide analogue within the preceding

81 e mode, to characterize RNA modifications at nucleoside and oligonucleotide levels.

82 cking lesions generated by chain-terminating nucleosides and alkylating agents, and base oxidation bo

83 also extract the monosaccharide ribose from nucleosides and characterize proteins necessary for its

84 metabolites comprised ten amino acids, four nucleosides and nucleobases, lactate, and vitamin E.

85 An analysis of the mechanisms by which nucleosides and nucleotides form in the solution phase o

86 hod for obtaining such 5-substituted hexitol nucleosides and nucleotides is described.

87 evelop a series of 3'-deoxy-7-deazaadenosine nucleosides, and investigate their effects against Afric

88 tives of peptides, sugars, natural products, nucleosides, and marketed drugs.

89 pes, do not respond to other nucleotides and nucleosides, and when fused with a red fluorescent prote

90 Formycin A is a potent purine nucleoside antibiotic with a C-glycosidic linkage betwee

91 C-Nucleosides are characterized by a C-C rather than a C-N

92 e, other resources such as nucleic acids and nucleosides are less studied.

93 Because of their physiochemical properties, nucleosides are lipid bilayer impermeable and thus rely

94 These species-independent A(3)AR-selective nucleosides are low efficacy partial agonists and novel,

95 Using these spirocyclopropanated nucleosides as key intermediates, we synthesized a varie

96 cellular dNTP and modulates the efficacy of nucleoside-based anti-cancer and anti-viral therapies.

97 perties are encapsulated and released from a nucleoside-based supramolecular gel and sets the basis f

98 Here, we use a novel nucleoside-based supramolecular gel as a drug delivery s

99 stituted 7-deazapurine and the corresponding nucleosides by coupling aryl or alkyl Grignard reagents

100 derivatives were prepared from nonprotected nucleosides by Pd-assisted Sonogashira or Suzuki-Miyaura

101 The reported clickable nucleosides can be utilized to functionalize or to cross

102 ies for late-stage modification of peptides, nucleosides, carbon nanotubes and electrodes, the detail

103 tly faster and higher yielding than that for nucleosides carrying linear alkynyl chains.

104 To identify and quantify the content of nucleoside compounds in the New Zealand native edible mu

105 The total concentration of the four nucleoside compounds was high, at 10.7 mg/g dry weight,

106 We characterized inorganic and nucleoside-conjugated linear and cyclic oligophosphates

107 ing of nascent DNA with 4-thio-thymidine and nucleoside conversion chemistry.

108 improved by 3 logs as compared to the parent nucleoside d4T.

109 Thus, this study indicates that nucleoside derivatives can exhibit varied modulatory eff

110 These results suggest that nucleoside derivatives, depending on structural function

111 of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transpo

112 When supplemented with only one purine nucleoside (dGuo), mtDNA copy number in both mutant and

113 and pyrimidine nucleosides, which represent nucleoside diphosphate analogues, and compared their CD7

114 ropose potential routes for the evolution of nucleoside diphosphate beta-l-Rha (NDP-beta-l-Rha) pathw

115 otein (Ap2), Rhomboid protein 1 (Rom 1), and nucleoside diphosphate kinase (NDK).

116 tidine protein kinase activity but retaining nucleoside diphosphate kinase (NDPK) activity showed tha

117 is and enzymatic activities of mitochondrial nucleoside diphosphate kinase (NDPK) in prostate cancer

118 e describe a new phagocytic function for the nucleoside diphosphate kinase 1 (NDK-1), the nematode co

119 goes endocytosis due to the induction of the nucleoside diphosphate kinase Abnormal Wing Disc (AWD).

120 The nucleoside diphosphate kinase NDK-1/NME1 promotes phagoc

121 Here, we characterized the M. oryzae nucleoside diphosphate kinase-encoding gene NDK1 and dis

122 ibits decapping by recombinant NUDT3 (Nudix [nucleoside diphosphate linked moiety X]-type hydrolase 3

123 either in the presence or absence of the non-nucleoside DNA methyltransferase (DNMT) inhibitors RG108

124 Inhibition of these events by non-nucleoside DNMT inhibitors represents a potential strate

125 2-Thiopyrimidine nucleosides exhibit properties that are interesting from

126 s in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-der

127 rs facilitate the passage of nucleobases and nucleosides for nucleotide synthesis and metabolism, and

128 A short and efficient synthesis of the nucleoside fragment contained in the NS5B nucleoside inh

129 rvirus and Fletchervirus Analysis of genomic nucleosides from several of these phages by high-pressur

130 We report the synthesis of the pyrimidine nucleosides from small molecules and ribose, driven sole

131 While most research on RNA nucleosides has been focused on their biological roles,

132 side reverse-transcriptase inhibitors and 37 nucleoside/heterocycle analogs were evaluated to identif

133 A vaginal ring containing dapivirine, a non-nucleoside human immunodeficiency virus (HIV)-1 reverse

134 ts of urate oxidase, xanthine dehydrogenase, nucleoside hydrolases, guanosine deaminase, and hypoxant

135 dentification of rigidified (N)-methanocarba nucleosides (i.e., compound 3 as a stimulator and compou

136 elevant compound, was shown to phosphorylate nucleosides in aqueous medium, albeit at a very slow rat

137 s facilitate 2'-O-methylation of a number of nucleosides in rRNA and promote protein translation.

138 kyl Grignard reagents and halogenated purine nucleosides in the presence of Fe(acac)(3)/CuI is descri

139 Particularly, the effect of the presence of nucleosides in unlocked nucleic acid (UNA), locked nucle

140 t compounds with rigidified (N)-methanocarba nucleosides inhibit the activity of P-gp; however, a flu

141 Structural analyses of nucleoside inhibitor binding provide insights into the c

142 he nucleoside fragment contained in the NS5B nucleoside inhibitor BMS-986094 was achieved in 23% over

143 ry infection), we identified GHP-88309-a non-nucleoside inhibitor of viral polymerase activity that p

144 Hepatitis C virus (HCV) nucleoside inhibitors display pan-genotypic activity, a

145 n and pentostatin are structurally related N-nucleoside inhibitors of adenosine deaminase characteriz

146 low membrane permeability inherent to known nucleoside inhibitors of CD73.

147 Non-nucleoside inhibitors of replication are reviewed in add

148 arget of five classes of naturally occurring nucleoside inhibitors with potent antibacterial activity

149 arget of five classes of naturally occurring nucleoside inhibitors with potent in vivo and in vitro a

150 er the past few years, notably in fusion and nucleoside inhibitors, and an update of the clinical sta

151 in, capuramycin, and mureidomycin classes of nucleoside inhibitors.

152 tereoselective to give desired beta-anomeric nucleoside intermediate 17A.

153 ion were explored to prepare the penultimate nucleoside intermediate.

154 for the incorporation of modified pyrimidine nucleosides into cellular RNA and expands the chemical t

155 recognition pattern of 5-aza-7-deazaguanine nucleosides makes them valuable for construction of homo

156 mans, two unrelated protein families mediate nucleoside membrane transport: the concentrative and equ

157 has been associated only with nucleotide and nucleoside metabolism.

158 ploiting their ability for RNA labelling and nucleoside modification recognition.

159 MS/MS analysis, we were able to identify the nucleoside modifications.

160 d that a single dose of a lipid nanoparticle nucleoside-modified messenger RNA vaccine encoding the s

161 genicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding th

162 nt, or lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA encoding full-length gB.

163 Utilization of a novel vaccine platform, nucleoside-modified mRNA formulated in lipid nanoparticl

164 th BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor bindi

165 BNT162b1 is a lipid-nanoparticle-formulated, nucleoside-modified mRNA vaccine that encodes the trimer

166 ody responses and the antibodies elicited by nucleoside-modified mRNA vaccines do not show antibody-d

167 Our findings suggest that the nucleoside-modified mRNA-LNP vaccine platform can induce

168 ether, these data suggest that the use of gB nucleoside-modified mRNA-LNP vaccines is a viable strate

169 gB nucleoside-modified mRNA-LNP-immunized rabbits exhibited

170 or one of two lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, wh

171 BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion

172 Although these inhibitors each have a nucleoside moiety, they vary dramatically in their core

173 argylamine and ethanolamine), fluoride, or a nucleoside monophosphate (uridine monophosphate, deoxyad

174 nsport rate between the nucleotide sugar and nucleoside monophosphate, suggesting a complex network o

175 n mechanism for enzyme-mediated release of a nucleoside monophosphate.

176 ment of ([PPN](2)[1]) with AMP or UMP yields nucleoside-monophosphate tetrametaphosphates (cp(4)pA, c

177 our naphthalimide dyes were designed to bind nucleoside monophosphates and oligonucleotides in an aqu

178 Among nucleoside/nucleotide reverse transcriptase inhibitors,

179 The most common ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (N

180 y of organohalogenated species, nucleobases, nucleosides, nucleotides, sulfonamides, and cyclic pepti

181 nfection; long-term follow-up of children on nucleoside or nucleotide analogue regimens to inform gui

182 to functionalize or to cross-link monomeric nucleosides or DNA for diagnostic or imaging purposes an

183 ridgehead nucleosides with respect to purine nucleosides permits the construction of new purine-purin

184 to isonitriles can be harnessed to activate nucleoside phosphates and carboxylic acids through catal

185 The ADPR analogues were obtained by coupling nucleoside phosphorimidazolides to deoxysugar phosphates

186 dditionally have adenosine deaminase, purine nucleoside phosphorylase, and S-methyl-5'-thioadenosine

187 s from products of an unlinked but essential nucleoside phosphorylase.

188 ursor) and urea-based solvents could promote nucleoside phosphorylation by transforming insoluble pho

189 owed the efficiency of 3-cyanovinylcarbazole nucleoside photo-inducible crosslinking on single molecu

190 Nucleosides play central roles in all facets of life, fr

191 escribed the discovery of GSK5852 (1), a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C vi

192 An asymmetric synthesis of HCV NS5B nucleoside polymerase inhibitor (1) is described.

193 ncer biology because oxidized purines in the nucleoside pool can significantly contribute to genetic

194 Adenosine is a potent immunoregulatory nucleoside produced during inflammatory states to limit

195 Likewise, administration of exogenous purine nucleosides protects sensitive GBM models from radiation

196 be electronically equivalent to natural DNA nucleoside radicals.

197 gent is used to introduce four phosphates on nucleosides regioselectively in a one-flask key transfor

198 and, via hemichannels, adenosine nucleotide/nucleoside release into the extracellular space.

199 The novel nucleoside rescue metabolic pathway proposed in this stu

200 at ART initiation (0.71 [0.61-0.82]) and non-nucleoside reverse transcriptase inhibitor (0.68 [0.51-0

201 r cells evaluated for drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at co

202 first-line antiretroviral therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus

203 oviral therapy (ART) for HIV patients is the nucleoside reverse transcriptase inhibitor (NRTI) is ten

204 Treatment of aged mice with the nucleoside reverse transcriptase inhibitor lamivudine do

205 side reverse transcriptase inhibitor (NNRTI)/nucleoside reverse transcriptase inhibitor PDR vs no PDR

206 group, five (63%) of eight had archived non-nucleoside reverse transcriptase inhibitor resistance-as

207 protease inhibitor (PI) lopinavir (LPV) and nucleoside reverse transcriptase inhibitor tenofovir ala

208 Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has show

209 eline HIV-1 RNA concentration and background nucleoside reverse transcriptase inhibitor therapy, to d

210 e safety profile, which support its use as a nucleoside reverse transcriptase inhibitor-sparing and p

211 the most common 3DR was dolutegravir plus 2 nucleoside reverse transcriptase inhibitors (46.9%).

212 weight gain than protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTI), wit

213 sted INIs (40%), boosted ARVs (30%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (32

214 Rising resistance of HIV-1 to non-nucleoside reverse transcriptase inhibitors (NNRTIs) thr

215 fic drugs and tallied major mutations to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nu

216 Prior exposure to both nucleoside reverse transcriptase inhibitors (NRTIs) and

217 Nucleoside reverse transcriptase inhibitors (NRTIs) are

218 ek) results of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can

219 d with ritonavir-boosted lopinavir, plus two nucleoside reverse transcriptase inhibitors (NRTIs) in a

220 Nucleoside reverse transcriptase inhibitors (NRTIs) were

221 e reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and

222 e reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and

223 d-line ART and cohorts B (B1, best available nucleoside reverse transcriptase inhibitors [NRTIs] plus

224 ed resistance; 1 EFV, emergent resistance to nucleoside reverse transcriptase inhibitors and nonnucle

225 sequent identification of thymidine analogue nucleoside reverse transcriptase inhibitors as the cause

226 ily) or efavirenz (EFV; 600 mg daily) with 2 nucleoside reverse transcriptase inhibitors for 52 weeks

227 7% of their infants received ineffective non-nucleoside reverse transcriptase inhibitors for PMTCT.

228 The antiviral activity of nucleoside reverse transcriptase inhibitors is often ham

229 l, and clinical responses to cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 riton

230 The regimen consisted of two nucleoside reverse transcriptase inhibitors plus nevirap

231 ent phase, without evidence of resistance to nucleoside reverse transcriptase inhibitors.

232 ir per day), both with investigator-selected nucleoside reverse transcriptase inhibitors: emtricitabi

233 (also known as ISL and MK-8591) is a unique nucleoside reverse transcriptase translocation inhibitor

234 CI 1749-2037; P = .002) regimens; and in non-nucleoside reverse transcription inhibitor-based (1563,

235 Nucleoside reverse-transcriptase inhibitors (NRTI), drug

236 Nine nucleoside reverse-transcriptase inhibitors and 37 nucle

237 PC786 is a nebulized non-nucleoside RSV polymerase inhibitor designed to treat RS

238 32 PI-treated persons; RT sequences from 333 nucleoside RT inhibitor (NRTI)-naive and 252 NRTI-treate

239 10.0% to 12.8% for NNRTIs, 4.1% to 8.1% for nucleoside RT inhibitors (NRTIs), and 3.6% to 5.2% for p

240 romes by substrate enhancement of the purine nucleoside salvage pathway and might improve the liver p

241 ction upon external stimuli and expansion of nucleoside salvage pathway genes potentially for competi

242 ped the active site residues responsible for nucleoside selection, metal coordination, triphosphate b

243 Most of the free nucleosides showed moderate to strong fluorescence with

244 Pyrene click adducts of linear alkynylated nucleosides showed pyrene monomer emission, while tripro

245 Deprotection gave the final nucleosides, some of which showed moderate cytotoxic and

246 to a variety of other interesting pyrimidine nucleoside structures.

247 This study further supports the idea that nucleoside supplementation has a potential therapeutic b

248 to reduce CIN by low doses of paclitaxel and nucleoside supplementation, respectively.

249 s opposed to what is usually observed during nucleoside synthesis using protected furanose precursors

250 shown to impact RNA degradation by inducing nucleoside tetraphosphate (Np(4)) capping of bacterial t

251 For the synthesis of modified nucleosides that will be the subject of biological testi

252 inhibition of viral replication as seen with nucleoside/tide analogs in other viral infections.

253 eoside analogues, mimics naturally occurring nucleosides to inhibit viral replication.

254 oside transporters (ENTs) 1 and 2 facilitate nucleoside transport across the blood-testis barrier (BT

255 ide a broad outlook on the current status of nucleoside transport research.

256 predict drug interactions with equilibrative nucleoside transporter (ENT) 1 and ENT2 using Bayesian m

257 ury via adenosine receptors or equilibrative nucleoside transporter (ENT)-dependent intracellular ade

258 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29

259 thymidine kinase 1 (TK-1), and equilibrative nucleoside transporter 1 (SLC29A1) in HCC compared with

260 KBP-dependent inhibitor of the equilibrative nucleoside transporter 1 and is efficacious in an animal

261 c adenosine transporter, ENT1 (equilibrative nucleoside transporter 1; Slc29a1), show no transition f

262 le-genome RNAi screening reveals that the P2 nucleoside transporter and adenosine kinase are involved

263 ansport: the concentrative and equilibrative nucleoside transporter families.

264 Equilibrative nucleoside transporters (ENTs) 1 and 2 facilitate nucleo

265 We will discuss the role played by nucleoside transporters in human health and disease, wit

266 We disclose a study on nucleoside triphosphate (NTP) analogues in which the gam

267 We developed a nucleoside triphosphate (NTP) delivery system (the TriPP

268 Nucleoside triphosphate analogues are presented, in whic

269 hesis and characterization of a new class of nucleoside triphosphate analogues comprising a C-alkyl-p

270 Such compounds formed gamma-C-(alkyl)-nucleoside triphosphate analogues with high selectivity

271 as molecular motors to couple the energy of nucleoside triphosphate binding and hydrolysis to mechan

272 Targeting nucleoside triphosphate hydrolase activity (CD39) toward

273 Under conditions of sepsis, agents with nucleoside triphosphate hydrolase activity decreased pla

274 ory potential of activated platelet targeted nucleoside triphosphate hydrolase activity, we employed

275 oteins are enriched in the P-loop containing nucleoside triphosphate hydrolases domain (P-loop).

276 proteins that couple the chemical energy of nucleoside triphosphate hydrolysis to the mechanical fun

277 cellular delivery of a stable gamma-modified nucleoside triphosphate to increase the selectivity of s

278 Using three isomers of a synthetic non-nucleoside triphosphate, we demonstrate that myosin's fo

279 and orientation of the template and incoming nucleoside triphosphate.

280 is of a broad range of natural and unnatural nucleoside triphosphates (dNTPs and xNTPs) using protoco

281 e a general and step-economical synthesis of nucleoside triphosphates and analogues on scale without

282 Natural and modified nucleoside triphosphates impact nearly every major aspec

283 d a high selectivity of these gamma-modified nucleoside triphosphates to act as substrates for HIV-RT

284 oxybenzyl-prodrugs of these gamma-ketobenzyl nucleoside triphosphates was prepared.

285 concentrations, covariation of magnesium and nucleoside triphosphates, and the effects of several typ

286 of cell types at high concentrations of 2'-F-nucleosides, typically not attained in vivo.

287 The noniodinated nucleoside was formed in 84%.

288 yzed click reaction on the tripropargylamino nucleoside was significantly faster and higher yielding

289 peptides and amino acids, whereas sugars and nucleosides were characteristic for wheat bread.

290 ence intensities of the 5-aza-7-deazaguanine nucleosides were higher than those of their 7-deazaguani

291 tituted 7-deazapurines and the corresponding nucleosides were obtained in medium to good yields.

292 In contrast to natural nucleosides, where the nucleobase is positioned at the a

293 c acid] derivatives of purine and pyrimidine nucleosides, which represent nucleoside diphosphate anal

294 Adenosine is a signaling nucleoside with potential opposing effects; adenosine ca

295 These nucleosides with a minimalistic triazolyl modification s

296 , we report the synthesis of pentopyranoside nucleosides with a phosphonate functionality at the 1'-a

297 trategy and leads to a set of CF(3)-modified nucleosides with different substitution patterns (C8, C2

298 incompatibility of modified nucleobases and nucleosides with nucleotide salvage pathways.

299 tion face of 5-aza-7-deazaguanine bridgehead nucleosides with respect to purine nucleosides permits t

300 e N(8)-glycosylated 8-aza-6-thiohypoxanthine nucleoside (X2) but only in the absence of canonical G a